Cargando…

Dapagliflozin reduces risk of heart failure rehospitalization in diabetic acute myocardial infarction patients: a propensity score-matched analysis

OBJECTIVE: The aim of this study was to investigate the effect of dapagliflozin (DAPA) on the rate of heart failure rehospitalization in patients with acute myocardial infarction (AMI) and type 2 diabetes mellitus (T2DM). METHODS: AMI patients with T2DM from CZ-AMI registry between January 2017 and...

Descripción completa

Detalles Bibliográficos
Autores principales: Mao, Lipeng, Cai, Dabei, Chi, Boyu, Xiao, Tingting, Zou, Ailin, Wang, Yu, Chen, Qianwen, Gu, Qingqing, Wang, Qingjie, Ji, Yuan, Sun, Ling
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10276777/
https://www.ncbi.nlm.nih.gov/pubmed/37099214
http://dx.doi.org/10.1007/s00228-023-03495-3
_version_ 1785060149620113408
author Mao, Lipeng
Cai, Dabei
Chi, Boyu
Xiao, Tingting
Zou, Ailin
Wang, Yu
Chen, Qianwen
Gu, Qingqing
Wang, Qingjie
Ji, Yuan
Sun, Ling
author_facet Mao, Lipeng
Cai, Dabei
Chi, Boyu
Xiao, Tingting
Zou, Ailin
Wang, Yu
Chen, Qianwen
Gu, Qingqing
Wang, Qingjie
Ji, Yuan
Sun, Ling
author_sort Mao, Lipeng
collection PubMed
description OBJECTIVE: The aim of this study was to investigate the effect of dapagliflozin (DAPA) on the rate of heart failure rehospitalization in patients with acute myocardial infarction (AMI) and type 2 diabetes mellitus (T2DM). METHODS: AMI patients with T2DM from CZ-AMI registry between January 2017 and January 2021 were enrolled in this study. Patients were stratified into DAPA users and non-DAPA users. The primary outcome was the incidence of heart failure rehospitalization. Kaplan–Meier analysis and Cox regressions were performed to evaluate the prognostic significance of DAPA. Propensity score matching (PSM) was performed to minimize the bias of confounding factors and facilitate the comparability between groups. The enrolled patients were matched with a propensity score of 1:1. RESULTS: A total of 961 patients were included, and 132 (13.74%) heart failure rehospitalizations occurred during a median follow-up of 540 days. In the Kaplan–Meier analysis, DAPA users had a statistically significantly lower rate of heart failure rehospitalization than non-DAPA users (p < 0.0001). Multivariate Cox analysis showed that DAPA was an independent protective factor for heart failure rehospitalization risk after discharge (HR = 0.498, 95% CI = 0.296 ~ 0.831, p = 0.001). After 1:1 propensity score matching, survival analysis showed a lower cumulative risk of heart failure rehospitalization in DAPA users than in non-DAPA users (p = 0.0007). In-hospital and continued use of DAPA remained significantly associated with a reduced risk of heart failure rehospitalization (HR = 0.417, 95% CI = 0.417 ~ 0.838, p = 0.001). Results were consistent across sensitivity and subgroup analyses. CONCLUSION: In patients with diabetic AMI, in-hospital and continued use of DAPA after discharge were associated with a significant lower risk of heart failure rehospitalization. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s00228-023-03495-3.
format Online
Article
Text
id pubmed-10276777
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Springer Berlin Heidelberg
record_format MEDLINE/PubMed
spelling pubmed-102767772023-06-19 Dapagliflozin reduces risk of heart failure rehospitalization in diabetic acute myocardial infarction patients: a propensity score-matched analysis Mao, Lipeng Cai, Dabei Chi, Boyu Xiao, Tingting Zou, Ailin Wang, Yu Chen, Qianwen Gu, Qingqing Wang, Qingjie Ji, Yuan Sun, Ling Eur J Clin Pharmacol Research OBJECTIVE: The aim of this study was to investigate the effect of dapagliflozin (DAPA) on the rate of heart failure rehospitalization in patients with acute myocardial infarction (AMI) and type 2 diabetes mellitus (T2DM). METHODS: AMI patients with T2DM from CZ-AMI registry between January 2017 and January 2021 were enrolled in this study. Patients were stratified into DAPA users and non-DAPA users. The primary outcome was the incidence of heart failure rehospitalization. Kaplan–Meier analysis and Cox regressions were performed to evaluate the prognostic significance of DAPA. Propensity score matching (PSM) was performed to minimize the bias of confounding factors and facilitate the comparability between groups. The enrolled patients were matched with a propensity score of 1:1. RESULTS: A total of 961 patients were included, and 132 (13.74%) heart failure rehospitalizations occurred during a median follow-up of 540 days. In the Kaplan–Meier analysis, DAPA users had a statistically significantly lower rate of heart failure rehospitalization than non-DAPA users (p < 0.0001). Multivariate Cox analysis showed that DAPA was an independent protective factor for heart failure rehospitalization risk after discharge (HR = 0.498, 95% CI = 0.296 ~ 0.831, p = 0.001). After 1:1 propensity score matching, survival analysis showed a lower cumulative risk of heart failure rehospitalization in DAPA users than in non-DAPA users (p = 0.0007). In-hospital and continued use of DAPA remained significantly associated with a reduced risk of heart failure rehospitalization (HR = 0.417, 95% CI = 0.417 ~ 0.838, p = 0.001). Results were consistent across sensitivity and subgroup analyses. CONCLUSION: In patients with diabetic AMI, in-hospital and continued use of DAPA after discharge were associated with a significant lower risk of heart failure rehospitalization. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s00228-023-03495-3. Springer Berlin Heidelberg 2023-04-26 2023 /pmc/articles/PMC10276777/ /pubmed/37099214 http://dx.doi.org/10.1007/s00228-023-03495-3 Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Research
Mao, Lipeng
Cai, Dabei
Chi, Boyu
Xiao, Tingting
Zou, Ailin
Wang, Yu
Chen, Qianwen
Gu, Qingqing
Wang, Qingjie
Ji, Yuan
Sun, Ling
Dapagliflozin reduces risk of heart failure rehospitalization in diabetic acute myocardial infarction patients: a propensity score-matched analysis
title Dapagliflozin reduces risk of heart failure rehospitalization in diabetic acute myocardial infarction patients: a propensity score-matched analysis
title_full Dapagliflozin reduces risk of heart failure rehospitalization in diabetic acute myocardial infarction patients: a propensity score-matched analysis
title_fullStr Dapagliflozin reduces risk of heart failure rehospitalization in diabetic acute myocardial infarction patients: a propensity score-matched analysis
title_full_unstemmed Dapagliflozin reduces risk of heart failure rehospitalization in diabetic acute myocardial infarction patients: a propensity score-matched analysis
title_short Dapagliflozin reduces risk of heart failure rehospitalization in diabetic acute myocardial infarction patients: a propensity score-matched analysis
title_sort dapagliflozin reduces risk of heart failure rehospitalization in diabetic acute myocardial infarction patients: a propensity score-matched analysis
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10276777/
https://www.ncbi.nlm.nih.gov/pubmed/37099214
http://dx.doi.org/10.1007/s00228-023-03495-3
work_keys_str_mv AT maolipeng dapagliflozinreducesriskofheartfailurerehospitalizationindiabeticacutemyocardialinfarctionpatientsapropensityscorematchedanalysis
AT caidabei dapagliflozinreducesriskofheartfailurerehospitalizationindiabeticacutemyocardialinfarctionpatientsapropensityscorematchedanalysis
AT chiboyu dapagliflozinreducesriskofheartfailurerehospitalizationindiabeticacutemyocardialinfarctionpatientsapropensityscorematchedanalysis
AT xiaotingting dapagliflozinreducesriskofheartfailurerehospitalizationindiabeticacutemyocardialinfarctionpatientsapropensityscorematchedanalysis
AT zouailin dapagliflozinreducesriskofheartfailurerehospitalizationindiabeticacutemyocardialinfarctionpatientsapropensityscorematchedanalysis
AT wangyu dapagliflozinreducesriskofheartfailurerehospitalizationindiabeticacutemyocardialinfarctionpatientsapropensityscorematchedanalysis
AT chenqianwen dapagliflozinreducesriskofheartfailurerehospitalizationindiabeticacutemyocardialinfarctionpatientsapropensityscorematchedanalysis
AT guqingqing dapagliflozinreducesriskofheartfailurerehospitalizationindiabeticacutemyocardialinfarctionpatientsapropensityscorematchedanalysis
AT wangqingjie dapagliflozinreducesriskofheartfailurerehospitalizationindiabeticacutemyocardialinfarctionpatientsapropensityscorematchedanalysis
AT jiyuan dapagliflozinreducesriskofheartfailurerehospitalizationindiabeticacutemyocardialinfarctionpatientsapropensityscorematchedanalysis
AT sunling dapagliflozinreducesriskofheartfailurerehospitalizationindiabeticacutemyocardialinfarctionpatientsapropensityscorematchedanalysis